// App-Quantinova.ai

476 : Body weight loss (BWL) as a prognostic/predictive factor in previously treated patients (pts) with metastatic gastric or gastroesophageal junction cancer (mGC/GEJC): Post-hoc analyses of the phase III tags trial.

Researchers

Presenter

  • Michele Ghidini

Principal Investigators

  • Howard S. Hochster

  • Toshihiko Doi

  • Eric Van Cutsem

  • Lukas Makris

  • Karim A. Benhadji

  • Wasat Mansoor

Medical Centers

  • Azienda Ospedaliera di Cosenza, Cosenza, Italy

  • Rutger-Cancer Institute, New Brunswick, NJ

  • National Cancer Center Hospital, Tokyo, Japan

  • University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium

  • Stathmi, Inc., New Hope, PA

  • Taiho Oncology Inc., Princeton, NJ

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

Locations

  • Italy

  • United States

  • Japan

  • Belgium

  • United Kingdom

Companies

  • Stathmi, Inc.

  • Taiho Oncology Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved